The 2012 TRCCC Annual Meeting was held on February 22-24, 2012 at Seven Spring Mountain Resort in Seven Springs, Pennsylvania.  The meeting focused on the latest activity in cancer vaccine and immune regulation, sharing progress on immunotherapy and related studies in the areas of:

• Adoptive cell therapy
• Innate immunity and tumor microenvironment
• Novel therapies
• Breast and GYN/ONC cancer
• Hematologic malignancy
• GI and urologic malignancy
• Melanoma
• Brain and other cancers

New to the conference in 2012 was the Advocate-Researcher Roundtable. TRCCC organizers felt the patient perspective was vital to this meeting, and welcomed survivor advocates to the 15th annual meeting in an to effort create dialogue between the research and patient communities in hopes of accelerating translational research. This new session was a great success and a welcomed addition to future TRCCC Annual Meetings.

• View photos from the meeting
• Read participant comments
• View the agenda for more information about the 2012 meeting
• View list of all abstract presentations from the 2012 meeting

First Place: Matthew Frigault, University of Pennsylvania
Chimeric Antigen Receptor (CAR) Signaling Can Induce Gain of Function Phenotype in T Cell Proliferation

Second Place: Jennifer Jacob, Karmanos Cancer Institute
Vaccination-induced pro-apoptotic antibodies to triple negative breast cancer (TNBC) with TRAIL death receptor DR5 DNA  

Third Place: Rafael Winograd, Abramson Family Cancer Research Institute
Unexpected T cell infiltration and tumor regression of spontaneous pancreatic cancer in mice following T cell priming outside the pancreatic tumor microenvironment   


Finalists:
William Buchser, University of Pittsburgh Cancer Institute
Cell Mediated Autophagy and Lysis are Regulated by Target Expression of HMBG1  

Maegan Capitano, Roswell Park Cancer Institute
A novel warming strategy for improving neutrophil recovery following total body irradiation   

Denarda Dangaj, Ovarian Cancer Research Center, University of Pennsylvania School of Medicine
Overcoming TAM-mediated T-cell inhibition using targeted therapeutics

Amy Haseley, The Ohio State University
Effect of CCN1 on macrophage activation following oncolytic virus therapy for glioma    

Nicholas Leigh, Roswell Park Cancer Institute
A novel TLR5 agonist, CBLB502, stimulates cytotoxic lymphocyte-mediated tumor immunity

Zhenzhen Liu, Ohio State University Comprehensive Cancer Center
IL-27 enhances anti-tumor CD8+ T cell responses via multiple mechanisms      

Jason Muhitch, Roswell Park Cancer Institute
Overcoming obstacles to naïve T lymphocyte trafficking in tumor-draining lymph nodes

Jeffrey Wojton, The Ohio State University

SapC-DOPS targeting and antitumor activities mediated by phosphatidylserine exposure